[Chapter 1. The challenges of pricing innovative drugs]. / Chapitre 1. Les enjeux de la fixation des prix des médicaments innovants.

Several innovative drugs including the first gene therapy drugs are expected shortly. In light of the debates on the new products for the treatment of hepatitis C and cancer, this wave of innovation raises questions about the ability of our health insurance systems to bear the expense and pay the price claimed by the laboratories. This situation has led to a reflection on the criteria for setting the price of drugs. Public authorities have developed new regulatory mechanisms and have opened a debate to explore new rules that would take into account - in the construction of contracts and prices - real world evidence.